Rampart Bioscience Secures $85 Million Funding to Revolutionize Gene Therapy Landscape

Rampart Bioscience is thrilled to announce the successful completion of a funding round, raising an impressive $85 million to further advance its revolutionary approach to treating genetically driven diseases.

This significant capital injection will enable Rampart to enhance its innovative non-viral DNA delivery system, a cornerstone of its mission to establish a new class of medicines that prioritize potency, durability, redosability, and safety.

By integrating expertise from diverse scientific disciplines, including gene delivery, protein sciences, and clinical translation, Rampart aims to push the boundaries of what is possible in gene therapy and provide patients with more effective treatment options.

The new funding will primarily be allocated towards accelerating clinical trials, optimizing their technology, and expanding their research capabilities to meet the urgent needs of patients grappling with genetic disorders.

With the goal of reshaping the treatment landscape for those who desperately require better alternatives, Rampart Bioscience is poised to make a significant impact on the lives of countless individuals.

The company’s dedication to innovating beyond the limitations of current therapies positions it as a leader in the biopharmaceutical industry, making strides towards delivering transformative therapies that can offer hope to patients worldwide.

As we embark on this exciting journey, we extend our gratitude to our investors for their trust and commitment to our vision, which ultimately aims to bring forth effective solutions for complex genetic diseases.